Androgen Receptor Highjacks ErbB-2 Nuclear Function to Induce Triple Negative Breast Cancer Growth
نویسندگان
چکیده
Abstract Triple negative breast cancer (TNBC) has poor prognosis and neither established biomarkers nor therapeutic targets. On the one hand androgen receptor (AR), a steroid hormone (SR) which is expressed in 10-53% of TNBC proved to be critical for BC proliferation, been proposed as new target TNBC. other hand, we others have shown that membrane ErbB-2 migrates nucleus (nuclear ErbB-2, NErbB-2) where it binds DNA at HER-2 associated sequences (HAS) regulate proliferation migration. Since previously functional interplay between growth factors SR signaling pathways BC, propose existence an interaction AR involved NErbB-2+/AR+ growth. The experimental model used was human cell line MDA-MB-453 displays high expression levels NErbB-2. By Western Blot (WB) found dihydrotestosterone (DHT) treatment short times (minutes) did not phosphorylation status residues Tyr1221/1222 1248 were constitutively activated. However, DHT led increase residue Tyr877 required nuclear latter effect blocked by antagonist enzalutamide (enza). Blockage Src activity with dasatinib inhibited DHT-induced Tyr877. Immunofluorescence confocal microscopy analyses subcellular fractionation studies demonstrated induced migration enza. chIP recruitment HAS site ERK5, gene FKBP5, classical responsive gene. WB transfection mutant unable translocate functions dominant inhibitor (hErbB-2ΔNLS), FKBP51 up-regulation DHT. Finally, microarray bioinformatics analysis identified 315 differentially genes (DEGs) presence NErbB-2 eviction. Enrichment showed DEGs belonged immune response interferon pathways. Kaplan-Meier revealed 6 significantly overall survival patients from METABRIC cohort: CXCL10, TAP1, STAT1, NMI, HLA-A NLRC5. Multivariate Cox regression combined independent predictor better clinical outcome (HR: 0.56, 95% CI 0.38-0.82, P = 0.003). In conclusion, our findings evidence DHT-activated induces Src-mediated rapid activation its sites DNA. Moreover, based on eviction signature favorable
منابع مشابه
Androgen Receptor Expression and Its Correlation with Clinicopathological Parameters in Iranian Patients with Triple Negative Breast Cancer
Background & Objective: Our knowledge about correlation of androgen receptor expression and clinicopathological properties of triple-negative breast cancer (TNBC) patients is inadequate, particularly in the Iranian population. The main aim of the present study was to assess the AR expression in TNBC Iranian patients and evaluate its correlation with their clinicopathological pa...
متن کاملRole of the androgen receptor in triple-negative breast cancer.
Triple-negative breast cancer (TNBC) is an aggressive disease with outcomes inferior to those of other breast cancer subtypes. No targeted therapies are currently approved for TNBC, and newer treatment approaches are critically needed. It is increasingly recognized that TNBC is a heterogeneous disease, and the role of androgen signaling in a subset of TNBC is emerging. Although the degree of an...
متن کاملErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy.
Approximately 15-20% of breast cancers (BC) show either membrane overexpression of ErbB-2 (MErbB-2), a member of the ErbBs family of receptor tyrosine kinases, or ERBB2 gene amplification. Until the development of MErbB-2-targeted therapies, this BC subtype, called ErbB-2-positive, was associated with increased metastatic potential and poor prognosis. Although these therapies have significantly...
متن کامل2. Role of the androgen receptor in triple-negative breast cancer
Triple-negative breast cancer (TNBC) accounts for 15% to 25% of breast-cancer diagnoses. TNBC expresses neither estrogen nor progesterone receptors, nor does it overexpress human epidermal growth factor type-2 receptor. It is an aggressive form of cancer and has not been a specific target of therapies for breast cancer. While it is initially sensitive to chemotherapy, TNBC has a high rate of re...
متن کاملNuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
Triple-negative breast cancer (TNBC) is a subclass of breast cancers (i.e., estrogen receptor-negative, progesterone receptor-negative, and HER2-negative) that have poor prognosis and very few identified molecular targets. Strikingly, a high percentage of TNBCs overexpresses the EGF receptor (EGFR), yet EGFR inhibition has yielded little clinical benefit. Over the last decade, advances in EGFR ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Endocrine Society
سال: 2021
ISSN: ['2472-1972']
DOI: https://doi.org/10.1210/jendso/bvab048.1635